GSK, Angiochem to develop drugs for lysosomal disease symptoms

02/27/2012 | Reuters

GlaxoSmithKline and Angiochem agreed to develop treatments intended to relieve neurological symptoms related to lysosomal storage diseases. Angiochem could get more than $300 million, including as much as $31.5 million upfront, plus sales royalties.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX